MARKET

XENT

XENT

Intersect ENT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.18
-0.64
-2.69%
After Hours: 23.18 +0.03 +0.11% 16:10 03/08 EST
OPEN
23.84
PREV CLOSE
23.82
HIGH
24.58
LOW
23.05
VOLUME
408.37K
TURNOVER
--
52 WEEK HIGH
26.98
52 WEEK LOW
5.97
MARKET CAP
757.61M
P/E (TTM)
-12.5014
1D
5D
1M
3M
1Y
5Y
Intersect ENT Q4 2020 Earnings Preview
Intersect ENT (NASDAQ:XENT) is scheduled to announce Q4 earnings results on Tuesday, March 9th, before market open.The consensus EPS Estimate is -$0.32 (-28.0% Y/Y) and the consensus Revenue Estimate is
Seekingalpha · 7h ago
Notable earnings before Tuesday's open
[[CMD]], [[DKS]], [[PLCE]], [[PQG]], [[THO]], [[XENT]]For Seeking Alpha's full earnings season calendar, click here.
Seekingalpha · 7h ago
A Preview Of Intersect ENT's Earnings
Intersect ENT (NASDAQ:XENT) releases its next round of earnings this Tuesday, March 09. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report. Net Income, Earnings, And Earnings Per Share Earnings and especially earni...
Benzinga · 11h ago
Sinus Dilation Devices Market Share, Size to Register Substantial Growth Through 2025 - Live Now
Mar 08, 2021 (Market Insight Reports) -- According to the research report titled 'Sinus Dilation Devices Market Size By Product, By Procedure, By End-use...
Market Insight Reports · 12h ago
CMS Consolidates SINUVA Sinus Implant Coverage Under a Distinct Code, J7402, and Publishes an ASP Clarifying Payment and Easing Payer Coverage Adjudication
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced...
BusinessWire - BZX · 14h ago
Sinus dilation devices market is projected to showcase 9.1% CAGR during the forecast period. | ARC
pune, India, Mon, 08 Mar 2021 00:43:16 / Comserve Inc. / -- The global sinus dilation devices market is project to reach USD 4.0 billion by 2026 in terms of...
Comserve · 20h ago
Why Earnings Season Could Be Great for Intersect ENT (XENT)
Zacks.com · 3d ago
Why Earnings Season Could Be Great for Intersect ENT (XENT)
Zacks.com · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XENT. Analyze the recent business situations of Intersect ENT through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XENT stock price target is 23.00 with a high estimate of 32.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 210
Institutional Holdings: 40.19M
% Owned: 122.82%
Shares Outstanding: 32.72M
TypeInstitutionsShares
Increased
34
3.31M
New
40
122.31K
Decreased
41
2.71M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.72%
Healthcare Equipment & Supplies
-1.34%
Key Executives
Non-Executive Chairman
Kieran Gallahue
President/Chief Executive Officer/Director
Thomas West
Chief Financial Officer/Executive Vice President
Richard Meier
Chief Operating Officer/Executive Vice President
Christine Kowalski
Chief Human Resource Officer
Reyna Fernandez
Executive Vice President/General Counsel/Secretary
Patrick Broderick
Independent Director
Teresa Kline
Independent Director
Cynthia Lucchese
Independent Director
Dana Mead
Independent Director
William Vernon
No Data
About XENT
Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.

Webull offers kinds of Intersect ENT Inc stock information, including NASDAQ:XENT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XENT stock methods without spending real money on the virtual paper trading platform.